---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-23-012579"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2023-09-22T23:59:59+00:00"
generated_at: "2026-06-10T09:42:31.844091+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro granted Nasdaq extension to Nov 15, 2023; must execute reverse stock split by Nov 1

## Summary
- Nasdaq Hearings Panel grants extension until Nov 15, 2023 to regain $1.00 minimum bid compliance.
- Conditions: obtain stockholder approval for reverse stock split (ratio 1:2 to 1:20) by Sept 29, 2023.
- Company must effect reverse stock split by Nov 1, 2023 and then maintain $1.00 closing bid for 10 consecutive business days.
- Annual stockholder meeting scheduled for Sept 29, 2023 to approve reverse stock split.

## SEC filing metadata
- accession: 0001214659-23-012579
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2023-09-22T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465923012579/0001214659-23-012579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465923012579/z9212308k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-23-012579
- JSON: https://secwatch.observer/filing/0001214659-23-012579.json
- Plain text: https://secwatch.observer/filing/0001214659-23-012579.txt

## Key facts
- Listing & Compliance Notices
  Alzamend Neuro, Inc. received a nasdaq extension granted notice regarding minimum bid price.
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  source text: September 22, 2023, the Company issued a press release to announce the extension granted by the Nasdaq Hearings Panel. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. In accordance with General Instruction B.2 of Form 8-K, the information under this item shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific referen
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465923012579/0001214659-23-012579-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.